180 related articles for article (PubMed ID: 21654517)
21. An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.
Ng PP; Dela Cruz JS; Sorour DN; Stinebaugh JM; Shin SU; Shin DS; Morrison SL; Penichet ML
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10706-11. PubMed ID: 12149472
[TBL] [Abstract][Full Text] [Related]
22. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
23. Binding specificity and internalization properties of an antibody-avidin fusion protein targeting the human transferrin receptor.
Rodríguez JA; Helguera G; Daniels TR; Neacato II; López-Valdés HE; Charles AC; Penichet ML
J Control Release; 2007 Dec; 124(1-2):35-42. PubMed ID: 17884229
[TBL] [Abstract][Full Text] [Related]
24. Development of a complete human IgG monoclonal antibody to transferrin receptor 1 targeted for adult T-cell leukemia/lymphoma.
Shimosaki S; Nakahata S; Ichikawa T; Kitanaka A; Kameda T; Hidaka T; Kubuki Y; Kurosawa G; Zhang L; Sudo Y; Shimoda K; Morishita K
Biochem Biophys Res Commun; 2017 Mar; 485(1):144-151. PubMed ID: 28189691
[TBL] [Abstract][Full Text] [Related]
25. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.
Ozaki S; Kosaka M; Wakatsuki S; Abe M; Koishihara Y; Matsumoto T
Blood; 1997 Oct; 90(8):3179-86. PubMed ID: 9376601
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic activity of an anti-transferrin receptor immunotoxin on normal and leukemic human hematopoietic progenitors.
Cazzola M; Bergamaschi G; Dezza L; D'Uva R; Ponchio L; Rosti V; Ascari E
Cancer Res; 1991 Jan; 51(2):536-41. PubMed ID: 1985771
[TBL] [Abstract][Full Text] [Related]
28. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
29. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
[TBL] [Abstract][Full Text] [Related]
30. Transferrin receptor 1: a target for antibody-mediated cancer therapy.
Daniels-Wells TR; Penichet ML
Immunotherapy; 2016 Sep; 8(9):991-4. PubMed ID: 27373880
[No Abstract] [Full Text] [Related]
31. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
32. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
33. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
[TBL] [Abstract][Full Text] [Related]
34. Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein.
Ye Q; Hu H; Wang Z; Lu T; Hu Z; Zeng X; Zhang S; Liu J; Lei P; Wang CY; Ye Z; Shen G
BMC Biotechnol; 2012 Nov; 12():91. PubMed ID: 23192001
[TBL] [Abstract][Full Text] [Related]
35. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
[TBL] [Abstract][Full Text] [Related]
36. DuoHexaBody-CD37
Oostindie SC; van der Horst HJ; Kil LP; Strumane K; Overdijk MB; van den Brink EN; van den Brakel JHN; Rademaker HJ; van Kessel B; van den Noort J; Chamuleau MED; Mutis T; Lindorfer MA; Taylor RP; Schuurman J; Parren PWHI; Beurskens FJ; Breij ECW
Blood Cancer J; 2020 Apr; 10(3):30. PubMed ID: 32341336
[TBL] [Abstract][Full Text] [Related]
37. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
McEarchern JA; Oflazoglu E; Francisco L; McDonagh CF; Gordon KA; Stone I; Klussman K; Turcott E; van Rooijen N; Carter P; Grewal IS; Wahl AF; Law CL
Blood; 2007 Feb; 109(3):1185-92. PubMed ID: 17038522
[TBL] [Abstract][Full Text] [Related]
38. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
[TBL] [Abstract][Full Text] [Related]
39. Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement.
Vankemmelbeke M; McIntosh RS; Chua JX; Kirk T; Daniels I; Patsalidou M; Moss R; Parsons T; Scott D; Harris G; Ramage JM; Spendlove I; Durrant LG
Cancer Res; 2020 Aug; 80(16):3399-3412. PubMed ID: 32532823
[TBL] [Abstract][Full Text] [Related]
40. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
Sekimoto E; Ozaki S; Ohshima T; Shibata H; Hashimoto T; Abe M; Kimura N; Hattori K; Kawai S; Kinoshita Y; Yamada-Okabe H; Tsuchiya M; Matsumoto T
Cancer Res; 2007 Feb; 67(3):1184-92. PubMed ID: 17283154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
